What's actually happening in the joint.
"Arthritis" is an umbrella term for more than a hundred joint conditions, but two account for the overwhelming majority of cases we see clinically: osteoarthritis (OA) and inflammatory arthritis (most commonly rheumatoid arthritis). They share a final symptom, pain, but the underlying biology is very different.
Osteoarthritis is a progressive disorder of the entire joint. The classic story is articular cartilage breakdown, but the disease also involves the underlying bone, the synovium, the meniscus (in the knee), the joint capsule, and surrounding ligaments and muscles. Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) perpetuate the cycle: inflammation drives further cartilage matrix degradation, which drives more inflammation.[3] By the time a patient reaches imaging-confirmed OA, the joint environment has been remodeling for years.
Rheumatoid arthritis and other inflammatory arthropathies start at a different node: the immune system attacks the synovium, producing a thickened pannus that erodes cartilage and bone from the inside. Disease-modifying drugs (DMARDs, biologics) are the standard of care and remain so. Regenerative protocols are not a substitute. They can, in selected patients with controlled disease and residual joint damage, be a useful adjunct.
Standard non-surgical care (NSAIDs, intra-articular corticosteroids, hyaluronic acid) primarily targets symptoms. It does not change the underlying tissue trajectory; in fact, repeated corticosteroid injections may accelerate cartilage loss in some patients.[4] Joint replacement is highly effective at the end of the road, but its appropriate use is for advanced disease, not the patient with moderate OA who still has a decade of joint function left to preserve.
The mechanism, in plain English.
Mesenchymal stem cells (MSCs) work primarily through paracrine signaling. The cells release a complex of cytokines, growth factors, and exosomes that modulate the joint environment.[1] Practically, this means three things happen.
Dampen inflammation
Pro-inflammatory cytokines that perpetuate joint damage are turned down, breaking the cycle of degradation.
Nudge healing
Resident joint cells are signaled toward a repair phenotype rather than the degenerative one they were stuck in.
Recalibrate immunity
The local immune response shifts away from chronic activation toward homeostasis.
MSCs do not, in the imaging sense, regrow cartilage. What they appear to do is shift a chronically inflamed joint back toward homeostasis.
Randomized trials of intra-articular MSC injection for knee osteoarthritis have demonstrated meaningful pain reduction and functional improvement compared to hyaluronic acid controls,[2] with effects sustained at one-year follow-up in multiple cohorts.[5] A 2017 systematic review concluded that MSC injection produces clinically relevant improvements in pain and function with a favorable short-term safety profile, while also acknowledging that long-term comparative data is still limited.[3]
What TrueCell offers
We use Wharton's jelly umbilical-cord-derived MSCs (UC-MSCs) prepared in our ISO-accredited laboratory. Cell viability is verified before every infusion. Protocols are calibrated to the joint, the disease stage, and the patient:
- Single-joint intra-articular UC-MSC at doses ranging from 20–30M cells (mild OA) to 40–60M cells (moderate OA), with higher-dose protocols (up to 100M) reserved for indications such as avascular necrosis of the hip.
- UC-MSC + PRP combinations for cases where local growth-factor concentration adds value, particularly in tendinopathic involvement (rotator cuff, lateral epicondylitis, plantar fasciitis).
- Muse cell therapy (a multilineage-differentiating stress-enduring cell subset) delivered intravenously for systemic homing or by direct injection in select cases.[6]
- Multi-joint and bilateral packages for patients with polyarticular OA, sequencing the most symptomatic joints first.
- Systemic IV UC-MSC as an adjunct in patients with diffuse inflammatory burden.
The catalogue is a starting point. The actual protocol is built after Dr. Ruiz reviews your imaging, history, and prior treatments, and it can be modified during the consult based on what we find on physical examination.
Who this works for, and who it doesn't.
The strongest evidence for MSC therapy in arthritis is in early to moderate osteoarthritis: roughly Kellgren-Lawrence grades 1 through 3, where there is still cartilage to preserve and the joint architecture is largely intact. These patients consistently show the largest and most durable improvements in published trials.[2]
What we need to evaluate you
To produce an honest candidacy assessment, the consult physician will want to see:
- Imaging. An MRI of the affected joint within the last 12–18 months is ideal; a recent X-ray is the minimum.
- Recent labs. CBC, CMP, ESR/CRP, and (for inflammatory arthritis) RF, anti-CCP, ANA as relevant. We can order these locally if needed.
- Medication list, including DMARDs, biologics, anticoagulants, and any recent corticosteroid injections.
- History. Prior surgeries, prior injections, what you've already tried.
If we are not the right answer for your case, we will tell you. The consult is complimentary and there is no pressure to proceed.
From consult to recovery.
-
Before arrival
Video consult and protocol confirmation
You'll have a video consult with a board-certified physician before booking travel. Imaging and labs are reviewed; the protocol is confirmed (or revised, or declined). Concierge handles scheduling, hotel coordination, and pickup from San Diego.
-
Day of treatment
Same-day procedure, walk out the afternoon
Most single-joint protocols are a same-day procedure. Expect a 30–60 minute clinical visit: physical examination, image-guided intra-articular injection (ultrasound or fluoroscopy as appropriate), and a brief post-procedure observation period. Local anesthesia is used; sedation is not typically required.
-
First 72 hours
Light activity, acetaminophen preferred
Mild soreness and swelling at the injection site is common and usually resolves within 48–72 hours. Acetaminophen is preferred over NSAIDs in this window because nonsteroidal anti-inflammatories may blunt the early signaling we want the cells to do.
-
Weeks 1–6
Gradual return to baseline activity
Many patients begin to notice changes in pain or stiffness in the 4–6 week window, though this varies by indication and severity. Aftercare check-ins are scheduled at 2 and 6 weeks to track progress.
-
Months 3–6
Peak benefit for most patients
Pain reduction and functional gains continue to develop as the joint environment stabilizes. A 12-week structured follow-up assesses whether the protocol is on the expected trajectory.
-
Year 1+
Durability and repeat dosing
Trial data show benefits sustained at 12 months in a substantial portion of patients,[5] with some cohorts showing maintained improvement at two years and beyond.[3] Some patients elect to repeat at 12–24 months, particularly for high-demand joints or progressive disease, and limited data suggest repeat dosing may produce additional benefit.[2]
Safety
The largest published safety analysis (covering more than 2,300 adult patients receiving autologous stem cell therapy for orthopedic conditions) reported a low overall adverse event rate, with most events transient and self-limited.[7] Allogeneic UC-MSC therapy carries its own risk profile, but the most common reactions remain local injection-site soreness and short-lived flare.